跳至主要内容
临床试验/NCT04844567
NCT04844567已完成不适用

Virtual Reality Intervention Alleviates Dyspnea in Patients Recovering From COVID Pneumonia

Ecole Polytechnique Fédérale de Lausanne2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2020年11月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
26
试验地点
2
主要终点
Efficacy (Breathing Comfort & Discomfort)

研究概览

简要总结

The present COVID-19 Virtual Reality (COVVR) clinical study is performed to test the hypothesis that an immersive virtual reality (iVR)-based Digital Therapeutics (DTx), would alleviate dyspnea by improving breathing comfort in patients recovering from COVID-19 pneumonia presenting with persistent dyspnea. We will further evaluate participants' perceived awareness of and agency over their breathing movements. Finally, we will track patients' perceived benefits related to the iVR intervention and the feasibility of using COVVR in the clinic or at home.

详细描述

Persistent dyspnea is the experience of breathlessness that persists despite optimal treatment of the underlying pathophysiology, and results in physical, psychosocial disability for the patient. As observed for SARS-CoV and MERS-CoV patients, a significant portion of COVID-19 patients present with persistent respiratory physiological impairment and persistent breathlessness that may not be addressed with conventional respiratory treatment such as oxygen, bronchodilators, diuretics or non-invasive ventilation.

Previous research on respiration-related feedback in Virtual Reality (VR) has demonstrated strong and replicable effects of VR feedback over one's perceived sense of agency and control over one's virtually embodied respiration. Based on these studies, the VR intervention evaluated here aims to alleviate symptoms of perceived breathlessness.

This within-subject study will compare breathing comfort as well as breathing discomfort, prior, during, and after a VR intervention that provides embodied visual feedback of participants' on-going respiration. Primary outcomes include subjective reports from participants (breathing comfort and breathing discomfort) and the intervention's clinical feasibility. Secondary outcomes include subjective ratings on perceived embodiment and sense of agency, as well as changes in respiration rate and variability.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
Double (Participant, Care Provider)

盲法说明

Participants are naïve to the difference in interventions. Allocation was concealed to the care provider screening participants.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Recovering from COVID-19 pneumonia confirmed by RT-PCR for SARS-CoV-2
  • Presented with persistent dyspnea with a self-rated intensity of five or higher (out of ten) on a visual analog dyspnea scale. ( "Do you have difficulty breathing?" "On a scale of 0 to 10, with 0 being no difficulty to breathe and 10 being the worst difficulty to breathe that you can imagine, where do you rank?".) This dyspnea rating will only used as an inclusion criterion and not as an outcome.
  • Being able to give consent
  • Being able to understand and speak French or English

排除标准

  • Any unstable respiratory, neurological, and cardiac conditions
  • Any psychiatric illness
  • Montreal Cognitive Assessment (MoCA) score below 25.

结局指标

主要结局

Efficacy (Breathing Comfort & Discomfort)

时间窗: through study completion, an average of one year

Efficacy will be evaluated based on subjective feedback by the patients regarding their breathing comfort and discomfort, depending on the intervention. Subjective ratings will be measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree. Comfort item: "My breathing was enjoyable" Discomfort item: "I had difficulty breathing"

VR Intervention Feasibility

时间窗: through study completion, an average of one year

Feasibility will be evaluated using a feedback questionnaire, alongside open feedback. Agreement with the questionnaire items indicates better feasibility, acceptance, and perceived outcome. Ratings will be measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree. Satisfaction: Did you enjoy the VR experience? Rehabilitation: Would you like to continue using the device during your recovery? Hospital Use: Would you have liked to use this earlier during your stay at the hospital? Home Use: Would you like to continue using the device at home? Respiratory benefit: Do you think the VR feedback improved your breathing? Well-being benefit: Did the VR feedback make you feel better?

次要结局

  • Embodiment(through study completion, an average of one year)
  • Respiratory Rate Variability(through study completion, an average of one year)
  • Respiratory Rate(through study completion, an average of one year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Olaf Blanke

Professor Doctor

Ecole Polytechnique Fédérale de Lausanne

研究点 (2)

Loading locations...

相似试验